Parrucchiere Primo Piano

Multaq Warning : Individuals with chronic hepatitis B infection, especially those with cirrhosis, are at increased risk for development of hepatocellular carci­noma (primary liver cancer), as in Case 5. As noted previously, while relatively rare in the United States, hepatocellular carcinoma is the num­ber one or number two cause of cancer death in the world, especially in certain Asian and African countries. Individuals with hepatitis B and cirrhosis bear the greatest risk for development of hepatocellular carci­noma. Individuals with hepatitis and no cirrhosis are also at increased risk compared to the general population.

Chronic hepatitis B infection is separated into two distinguishable “states.” The best way to distinguish these two states of hepatitis B virus infection is by the presence or absence of hepatitis Be antigen (HBeAg) in blood. In instances where the hepatitis B virus is rapidly replicating, a short form of the hepatitis B core antigen, called HBeAg, is usually detected in the blood. HBeAg is detected in the blood dur­ing acute infection, when the virus rapidly replicates, and becomes undetectable as the acute infection resolves. In most cases of chronic infection, HBeAg is not detected because the virus enters a state of low replication and its genetic material integrates into the DNA of infected cells. In some cases of chronic infection, however, the virus maintains a highly replicative “lifestyle” (are viruses alive?) and, in most of these cases HBeAg will be detected in the blood. In individuals chronically infected with hepatitis B virus, the state of infection can switch from HBeAg-positive (high replication) to HBeAg-negative (low replication) at any time.

The distinction between HBeAg-positive and HBeAg-negative chronic hepatitis B is critical regarding disease severity, prognosis, con­tagiousness, and treatment. Patients who have HBeAg in their blood usually have more severe clinical disease with a greater amount of inflammation in the liver. They are usually sicker and have more symp­toms. The chances of progression to cirrhosis and hepatocellular car­cinoma are greater. In addition, individuals with detectable HBeAg in their blood are highly infectious as high viral replication is associated with the presence of more viral particles in the blood. A major goal of treatment for chronic hepatitis B is to convert a patient who has detectable HBeAg in the blood (a state of high virus replication) to one who does not have detectable HBeAg in the blood (a state of low-level virus replication). This change after treatment is associated with a bet­ter long-term prognosis.

More information on Multaq Warning

Individuals with chronic hepatitis B virus infection can sponta­neously convert from HBeAg-negative to HBeAg-positive. This is asso­ciated with worsening disease severity and prognosis. Paradoxically, conversion from HBeAg-positive to HBeAg-negative, which is associ­ated with a better long-term outlook, is associated with a transient worsening of hepatitis and higher elevations in blood ALT and AST activities. This probably occurs because the immune system attacks the hepatocytes in which the virus is rapidly replicating, causing increased liver inflammation and cell death as infected cells are killed. The “flare” in hepatitis associated with conversion from HBeAg-positive to HBeAg-negative usually resolves with improvement in condition.

An exception to the rule that HBeAg is detectable in the blood of individuals infected with the hepatitis B virus when the virus is rapidly replicating occurs when there is infection with mutant forms of hepati­tis B virus known as precore mutants. Precore mutants of the hepati­tis B virus have mutations in their core proteins. As a result, they do not make HBeAg, even when they are rapidly replicating. Therefore, in precore mutant infection, the presence or absence of HBeAg in the blood is not a determinant of prognosis. It may be suspected when patients do not have detectable HBeAg but do have high concentra­tions of hepatitis B virus DNA in the blood. Precore mutants are defin­itively identified only by isolating the virus irony the patient and exam­ining its DNA sequence.

Information from other sources on Multaq Warning

Approximately 350 million individuals throughout the world are chronically infected with the hepatitis B virus, making it the number one worldwide cause of liver disease. The geographic distribution of cases varies tremendously from one part of the world to another. Hepatitis B virus infection is relatively uncommon in the United States and other Western countries. In the United States, just over one mil­lion individuals are chronically infected with hepatitis B virus. On the other hand, hepatitis B virus infection is endemic in Southeast Asia and sub-Saharan Africa. In countries such as Senegal, Thailand, and parts of China, as many as 25 percent of the population may become infected with hepatitis B virus by early childhood.

Transmission of hepatitis B virus from mother to baby may occur either before delivery or by exposure to the mother’s blood at the time of delivery. The hepatitis B virus is also present in the breast milk of infected mothers, but a large study has shown that breast-feeding is not a major source of transmission of hepatitis B. Some babies of infected mothers who are not infected with the hepatitis B virus at birth become infected during the first few months or first year of life—prob­ably by household exposure to the mother’s blood or that of infected brothers or sisters.

A major route of transmission of hepatitis B in the West was trans­fusion of blood and blood products. Since the association of the Aus­tralia antigen with serum hepatitis in the 1960s, tremendous efforts have been taken to screen the blood supply and keep it free of hepati­tis B virus. In most industrialized countries, the risk of contracting hepatitis B from a blood transfusion is extremely low as donated blood is screened for the virus. In addition, intravenous drug users and other individuals at high risk for hepatitis B are excluded from donating blood if they are identified. Although the blood supply is remarkably safe, no screening test is perfect, and the risk of contracting hepatitis B from a transfusion of one unit of blood in the United States is approx­imately one in sixty thousand to one in one hundred thousand. The hepatitis B virus can also be transmitted by organ transplantation, but the organ donor’s blood is generally tested for hepatitis B virus infec­tion before an organ is used.

Our use of the term or terms Multaq Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Warning visit our site often.

http://www.seedol.com

Multaq Warning : If your doctor notes elevated levels of AP and GGTP enzymes in your blood, he or she will likely order an endoscopic retrograde cholangiopancreatogram. During a ERCP, patients are sedated, and a small lighted tube (called an endoscope) is inserted into the mouth and threaded through the small intestine until it reaches a tiny intestinal opening called the ampulla ofVater, which leads to the extrahepatic bile ducts. A thinner tube is inserted into the ducts, creating access for a contrast dye that highlights the ducts on an X-ray, enabling doctors to see them and determine if they are damaged.

If the bile ducts are narrowed and irregular, a diagnosis of PSC is confirmed. In some cases, narrowed bile ducts can be dilated or a stent (a small tube) can be inserted to keep a duct open. After these procedures, patients feel much better because bile flows more freely. Nonetheless, new narrowings can still develop.

Occasionally, if an ERCP is not available or cannot be per­formed, magnetic resonance cholangiopancreatography (MRCP) may be employed instead. An MRCP is an MRI that looks at the biliary tree. But the MRCP does not allow for dilation or stenting; it simply produces a diagnostic picture.

Primary sclerosing cholangitis does not follow a predictable course. Symptoms may persist at the same level, occur intermit­tently, or steadily progress. In some patients, 15 to 20 years may elapse before the liver deteriorates ro the point of failure and a transplant must be considered.

Because the disease progresses slowly, a biopsy will show the extent of damage to the liver, but a biopsy is rarely used to make the initial diagnosis. Primary sclerosing cholangitis follows a staging system that gives insight into the patient’s longer-term prognosis, with stage 1 indicating early scarring and narrowing of the bile ducts, and stage 4 carrying a diagnosis of cirrhosis.

More information on Multaq Warning

Primary sclerosing cholangitis is an incurable disease, but its symptoms can be treated and its progression slowed. To resolve itching, patients should sample the range of available medica­tions, including prescription medications such as cholestyramine (Questran), which binds bile salts in the intestine and allows them to be eliminated with stool, thereby reducing their accumulation in the liver and skin.

More serious complications of primary sclerosing cholangi­tis are osteoporosis and osteomalacia (bone-calcium deficiency). Patients are advised to increase their intake of calcium with vita­min D to boost absorption and to consider bone-density medica­tions if these conditions are noted on a bone-density scan. Gallstones, another complication frequently seen in primary sclerosing cholangitis patients, can be treated as they are in patients who do not have PSC. If infections occur in the bile ducts, they should be treated with antibiotics. Restricted salt intake as well as use of diuretics can help reduce swelling of the abdomen and feet, once PSC becomes cirrhosis. Patients who are deficient in vitamins A, D, and K can supplement their diets.

Information from other sources on Multaq Warning

Virtually every liver mass can be labeled as either benign (not cancerous) or malignant (cancerous). The only way to distinguish between the two is to perform a liver biopsy. Benign masses will not spread to other organs and may or may not pose problems.

Benign liver tumors occur in many forms, but five types are the most common: hemangiomas, hepatic adenomas, focal nodular hyperplasia, solitary liver cysts, and nodular regenerative hyper­plasia. Each of these liver masses has its own unique characteristics, symptoms, and treatments. Hemangiomas. As their name describes, hemangiomas are filled with heme, or blood. They closely resemble the harmless red spots known as senile hemangiomas, which spontaneously appear on the chests and abdomens of senior citizens. The most common type of benign liver tumor, hemangiomas are estimated to occur in up to 20 percent of the population; about one-tenth of affected individuals-—more women than men—will have more than one. Hemangiomas also occur in the brain, lungs, or skin, and they crop up at any age.

Hemangiomas almost always remain small, and because they usually cause no symptoms, most people with these masses are not aware they are diere. Occasionally, the hemangioma will grow larger than a few centimeters and begin to cause pain in the upper right quadrant of the abdomen. If the hemangioma continues to expand, the tumor can begin to bleed, sometimes forming blood clots within itself and causing pain. Hemangiomas rarely bleed into the abdominal cavity, but it does happen—and this is an extremely serious and painful event that calls for emergency surgery.

Typically, hemangiomas are discovered during a sonogram or CT scan for an unrelated disorder. If the mass is larger than two and one-half centimeters, a tagged red blood cell (RBC) scan—a test that dyes the blood with a radioactive metallic element called a tracer—may be ordered. The RBC scan is a lengthy test; it takes about two hours for the tracer to accumulate in the hemangioma before the diagnosis is confirmed.

Our use of the term or terms Multaq Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Warning visit our site often.

http://www.seedol.com

Multaq Warning : When a suitable donor liver becomes available, the person “whose turn it is” to receive the liver is either called (or paged) or informed in his or her hospital bed that it is time for surgery. Liver transplantation is orthotopic in that the new liver is put in the same place as the old one. The trickiest part of the surgery is probably attaching the bile duct from the new liver to the part of the recipient’s bile duct that remains in place. A major complication of liver transplant surgery is bleeding. Patients who undergo liver transplantation often have massive blood loss. Transfusion of many units of red blood cells, fresh frozen plasma, and platelets may be necessary.

After surgery, the patient is taken first to the recovery room and then the surgical intensive care unit. Most patients wake up within twenty-four hours after surgery while on a respirator. Some patients will need kidney dialysis for a few days after transplantation. The blood bilirubin concentration, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) activities are followed carefully to establish if the new liver is functioning properly or damaged. Medications to prevent rejection of the transplanted liver are begun at surgery and continued afterward. The concentrations of some of these medications in the blood are monitored closely, and they may have to be adjusted frequently. If all goes well, a patient can leave the hospital less than two
weeks after liver transplantation. Sometimes, complications arise that require longer hospital stays after surgery.

More information on Multaq Warning

Virtually all patients receiving liver transplants will take either cyclosporin A (Sandimmune orNeoral) or tacrolimus (Prograft), which used to be called FK506. Others may take sirohmus (Rapamune), which is of the same general class. Most patients will also take prednisone and azathioprine (Imuran), which are agents that act by different mechanisms to suppress the immune system. Others may take mycophenolate mofetil (CellCept). These drugs are started immediately after transplant surgery. Each of these drugs has different side effects, and doctors may change the drugs and adjust their doses depending upon the patient’s condition and adverse events experienced. These drugs are expensive, in most cases more than $10,000 a year. Most important, patients must take all of their immunosuppressive drugs as prescribed to prevent rejection. Failure to take these drugs can lead to severe rejection.

After discharge from the hospital, patients will generally return to see a doctor from the transplant team at least once a week for the first month or two. Laboratory tests will also be checked for evidence of rejection or liver graft dysfunction. Abdications may be adjusted depending upon laboratory test results. If the patient’s condition remains stable, the frequency of follow-up visits will be gradually decreased.

Rejection can usually be suspected according to blood test results. Most episodes of rejection will be detected by increases in blood ALT or AST activities. Rejection can be definitively diagnosed only by liver biopsy. If blood testing suggests rejection, liver biopsy will be performed. Most patients will experience some degree of rejection the first couple of weeks after liver transplantation. These rejection episodes are usually mild or moderate and respond to intravenous steroids (usually methylprednisolone) followed by a brief period of increased prednisone doses. Severe rejection episodes, or those not responding to steroids, are usually treated by intravenous administration of antibodies against lymphocytes, the white blood cells that attack the transplanted organ. These antibody drugs include muromonab-CD3 (Orthoclone OKT3), basiliximab (Simulect), and daclizumab (Zena- pax). About 10 percent of patients who undergo liver transplantation develop chronic rejection that does not respond to drugs. For these patients, a second transplant is the only option.

Infection is another common complication after organ transplantation. Because the immune system is suppressed by drugs, posttransplant patients are at risk for infections that patients with normally functioning immune systems are not. These include infection with Pneumocystis carinii, which causes pneumonia, and cytomegalovirus (CMV), which causes many problems including hepatitis in the new liver. Patients may take trimethoprim/sulfamethoxazole (Bactrim or Septra) to prevent Pneumocystis pneumonia. Patients may also take ganciclovir (Cytovene) to prevent CMV infection. CMV infection can mimic rejection, and the two can usually be differentiated only by liver biopsy. Many other infections that do not normally cause problems in people with normal immune systems, including those by fungi, Mycobacterium, and other viruses such as herpes simplex and herpes zoster, can occur.

Information from other sources on Multaq Warning

Another concern after liver transplantation is that the original disease will recur in the new organ. Autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis generally do not recur. If a former alcoholic does not drink, alcoholic liver disease will not occur. However, I have seen a case of alcoholic hepatitis in a patient who continued to drink after transplantation (usually such individuals will probably stop taking their immunosuppressive drugs and suffer severe rejection first). Patients who had cirrhosis from viral hepatitis B or C are at risk for the new liver to again become infected. Although the new liver is almost always reinfected with the hepatitis C virus in recipients who suffered from this disease, the degree of posttransplant hepatitis is usually mild. Severe and rapidly progressive hepatitis due to hepatitis C virus infection sometimes occurs in the transplanted liver, however. Hepatitis B virus reinfection of the new liver often leads to severe hepatitis and destruction. Fortunately, this can be prevented by drugs. Patients transplanted for cirrhosis from hepatitis B usually receive hepatitis B immune globulin (HBIG) and/or lamivudine, ade- fovir, or entecavir after transplantation.

Immunosuppressive drugs to prevent rejection have many adverse events. Among them are kidney damage and nervous system problems. If adverse events related to these drugs arise, the doctors may adjust the doses or switch from one agent to another similar one, such as from tacrolimus to cyclosporin A. In the long term, patients chronically receiving immunosuppressive agents are at increased risk for developing some types of cancer and, therefore, require monitoring.

People with liver diseases must live with their illnesses. This is sometimes difficult for their doctors to realize, and it is often difficult for family members and friends to realize. It is also sometimes difficult for patients to accept. Perhaps the most important advice for most people with chronic liver diseases is to keep the right attitude. Remain positive toward your day-to-day life and about your future.

Beyond keeping a positive attitude, it is impossible to give any specific recommendations that will help all patients with liver diseases live happily. First of all, there are many different chronic liver diseases, and the outlook for each is different. The prognosis for different patients with the same disease can also vary tremendously. Most patients with chronic hepatitis B or chronic hepatitis C will live full and essentially normal lives while a minority will develop cirrhosis and possibly liver cancer. Perhaps scariest of all is that you often cannot be sure what will happen to you. However, in many cases, the odds will be in your favor.

In an attempt to provide some general rules about living with liver disease, it is important to realize that some patients have very special needs. Most important to consider are patients with liver diseases who are actively abusing alcohol or other drugs or who are dependent upon alcohol or other substances. The social and psychological issues of patients who are substance abusers make their priorities quite different. Another small group of patients having special considerations are those with advanced cancer involving the liver. Such patients should probably seek out cancer support groups and foundations such as the American Cancer Society for information. Finally, young children have special needs that are different from adults. There are several support groups devoted to children with liver disease, and pediatricians should also prove helpful in these instances.

Our use of the term or terms Multaq Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Warning visit our site often.

http://www.seedol.com